English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduIn a new article published in Clinical Cancer Research, Moffitt Cancer Center researchers show that various subtypes of lung cancer cells activate different signaling pathways in response to KRASG12C inhibitor treatment. These results may help identify potential combination therapy approaches and guide treatment decisions for lung cancer patients in the future.
Tag: Lung Cancer
Deep learning may help doctors choose better lung cancer treatments
Doctors and healthcare workers may one day use a machine learning model, called deep learning, to guide their treatment decisions for lung cancer patients, according to a team of Penn State Great Valley researchers.
MD Anderson and Mirati Therapeutics announce KRAS strategic research and development collaboration in solid tumors
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati’s two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents – which target two of the most frequent KRAS mutations in cancer.
Black Lung Cancer Patients Die Sooner than White Counterparts
Structural racism thwarts a large proportion of black patients from receiving appropriate lung cancer care, resulting in worse outcomes and shorter lifespans than white patients with the disease, according to research presented at the 57th Annual Meeting of The Society of Thoracic Surgeons.
Missing Protein Helps Small Cell Lung Cancer Evade Immune Defenses
DALLAS – Jan. 25, 2021 – Small cell lung cancer (SCLC) cells are missing a surface protein that triggers an immune response, allowing them to hide from one of the body’s key cancer defenses, a new study led by UT Southwestern researchers suggests. The findings, reported online today in Cancer Research, a journal of the American Association for Cancer Research, could lead to new treatments for SCLC, which has no effective therapies.
New immunotherapy combination shows great promise for lung cancer, McMaster researchers find
Researchers at Canada’s McMaster University have established in lab settings that a novel combination of two forms of immunotherapy can be highly effective for treating lung cancer, which causes more deaths than any other form of cancer.
Media Advisory: Register for STS Annual Meeting and Press Briefings
Credentialed press representatives are invited to attend The Society of Thoracic Surgeons VIRTUAL 57th Annual Meeting. This interactive, fully digital experience—expected to be unlike anything that cardiothoracic surgery has experienced to date—will feature thought-provoking lectures, practice-changing science, and cutting-edge techniques and technologies.
Researchers Uncover A Potential Treatment For an Aggressive Form of Lung Cancer
DALLAS – Jan. 5, 2021 – Researchers at the Children’s Medical Center Research Institute at UT Southwestern (CRI) have discovered a new metabolic vulnerability in a highly aggressive form of non-small cell lung cancer (NSCLC). These findings could pave the way for new treatments for patients with mutations in two key genes – KRAS and LKB1. Patients whose tumors contain both of these mutations, known as KL tumors, have poor outcomes and usually do not respond to immunotherapy.
Yale study leads to FDA approval of drug to treat non-small cell lung cancer
Based on results of a clinical trial led by Yale Cancer Center researchers, the U.S. Food and Drug Administration has approved osimertinib for the treatment of adults with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations, which occurs in about 10 percent of patients.
Roy S. Herbst, MD, PhD, Receives 2020 ACCC Clinical Research Award
Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Associate Cancer Center Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital, has been selected as the 2020 Clinical Research Award recipient by the Association of Community Cancer Centers for significantly and positively impacting oncology patients, their families, and the broader oncology community.
Study reports drop in lung cancer screening, rise in malignancy rates during spring COVID-19 surge
Reporting on how deferred care worsened outcomes for lung cancer patients when the COVID-19 pandemic first surged in the spring of 2020, researchers from the University of Cincinnati explained that they have identified a framework that could help people with serious health conditions keep up their appointments during the current surge. The study has been selected for the 2020 Southern Surgical Association Program and published as an “article in press” on the Journal of the American College of Surgeons website in advance of print.
New combination therapy could help fight difficult-to-treat cancers with common mutations
UCLA scientists describe a new combination therapy that suppresses the MAPK pathway by holding cancer-driving proteins in a death grip. This combination of two small molecules has the potential to treat not only BRAF mutated melanoma but also additional aggressive subtypes of cancers, including melanoma, lung, pancreatic and colon cancers that harbor common mutations in cancer genes called RAS or NF1.
NYU Langone Health Expands Comprehensive Lung Cancer Care in Brooklyn
NYU Langone Health’s Perlmutter Cancer Center, a National Cancer Institute–designated Comprehensive Cancer Center, in partnership with NYU Langone Hospital–Brooklyn is growing its state-of-the-art lung cancer care in New York City’s largest borough with a new expansion of treatment and screening services.
Study identifies patients with lung cancer most likely to respond to immunotherapy
Researchers at the UCLA Jonsson Comprehensive Cancer Center found patients with a particular type of human leukocyte antigen (HLA), a protein scaffold involved in presenting pieces of proteins described as peptides to the immune system, were particularly likely to benefit from immunotherapy.
Researcher receives $2.9 million NCI grant to improve lung cancer radiation therapy
An Indiana University Melvin and Bren Simon Comprehensive Cancer Center researcher has been awarded a five-year, $2.9 million grant from the National Cancer Institute to develop a drug that could make radiation therapy far more effective.
MD Anderson researchers present immunotherapy advances at Society for Immunotherapy of Cancer Annual Meeting
Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) .
Compounds in Active Muscles May Help Slow Lung Cancer Growth
Lung cancer is one of the most common cancers in the U.S. and accounts for roughly 25% of all cancer deaths. Patrick Ryan, MS, from Texas A&M University, and his research team found that treating cultured lung cancer cells with blood collected from contracting muscles—muscles that were exercised—did not grow as much as untreated cells.
Lung cancer experts provide knowledge on treatment innovations, tips for successful smoking cessation and more
With Lung Cancer Awareness Month upon us, Indiana University Melvin and Bren Simon Comprehensive Cancer Center’s scientists, physician-scientists, and staff are available to offer expertise in treatment innovations, the biology of lung cancers, research initiatives, and tips for successful smoking…
New lung cancer treatments lead to vastly improved survival rates
UCLA Health has helped drive monumental advances in the treatment of lung cancer – increasing survival rates in the nation’s leading cause of cancer deaths.
Racial Disparities in Treatment for Common Lung Cancer Persist Despite Gains
African American patients with lung cancer are still less likely to receive the most effective treatment for a common type of early stage lung cancer.
DERMATOLOGIST SAVES SOUTH FLORIDA MAN’S LIFE WITH EARLY DIAGNOSIS OF LUNG CANCER
The American Academy of Dermatology named board-certified dermatologist Brittany Smirnov, DO, FAAD, a Patient Care Hero for her role in diagnosing and treating a patient with stage IV metastatic lung cancer.
CWRU and UH Researchers Secure $4 Million in NCI Funding to Investigate Relationships between HIV and Lung Cancer in East Africa
Researchers with the Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have secured $4 million in funding from the National Institutes of Health (NIH)/National Cancer Institute (NCI) to establish an HIV-associated Malignancy Research Center focused on lung cancer in East Africa.
Mount Sinai Selected to Serve as Capacity Building Center and Center of Excellence as Part of the National Cancer Institute’s New Serological Sciences Network
Researchers from the Icahn School of Medicine at Mount Sinai will receive more than $7.3 million from the National Cancer Institute (NCI) as part of the NCI’s new Serological Sciences Network (SeroNet), one of the largest coordinated national efforts to study immunology and SARS-CoV-2, the virus that causes COVID-19. Mount Sinai was selected as one of only four Capacity Building Centers and one of eight Centers of Excellence as part of this new network.
Yale Trial Validates Immunotherapy Treatment for Non-Small Cell Lung Cancer
The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer, according to a new study led by Yale Cancer Center researchers.
Study Reinforces Benefit Using Targeted Therapy for Early Stage NSCLC
According to updated findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery continues to significantly improve disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations.
KRAS inhibitor sotorasib appears safe, achieves durable clinical benefit in early trial
For patients with advanced solid cancers and KRAS G12C mutations, the targeted therapy sotorasib, a KRAS G12C inhibitor, resulted in manageable toxicities and durable clinical benefits, particularly in lung and colorectal cancer, in Phase I study
Cancer Research Institute Goes Virtual for Its Immunotherapy Patient Summit Series, Connecting Patients and Caregivers with Leading Experts in Cancer Immunotherapy
Free virtual event October 2-3 connecting cancer patients and caregivers with leading immunotherapy experts and patient advocates treated with immunotherapy
Why The Dose Matters: Study Shows Levels And Anti-Tumor Effectiveness of A Common Drug Vary Widely
DALLAS – Sept. 17, 2020 – When used to manage infections, the drug itraconazole is generally given at a single, fixed dose to all patients. But determining the correct dosage of the drug to help treat cancer isn’t that simple, new research by UT Southwestern suggests.
New study from MD Anderson and BridgeBio’s Navire Pharma shows SHP2 inhibition overcomes multiple therapeutic-resistance mechanisms in lung cancer
New preclinical research from MD Anderson and Navire finds a novel drug targeting SHP2 can overcome multiple paths of therapeutic resistance in lung cancer. Navire will launch a clinical trial of SHP2 inhibitors by the end of 2020.
Colorado Cancer Screening Program Earns Another Year of Funding
July 1, 2020 marked the start of another year of funding for the Colorado Cancer Screening Program (CCSP) for Patient Navigation but just like most things in 2020… it’s not just another year for a decade long program.
Robotic Lung Cancer Surgery Comes to NYU Langone Hospital–Brooklyn
Travis Geraci, MD, a specialist in minimally invasive robotic lung and esophageal cancer surgery, will spearhead an expansion of cardiothoracic surgical services in Brooklyn.
Researchers identify RNA molecule that helps lung cancer cells evade immune system
Researchers in Spain have identified a non-coding RNA molecule that helps lung cancer cells proliferate and avoid being killed by the body’s immune cells. The study, which will be published August 27 in the Journal of Cell Biology (JCB), suggests that targeting this RNA molecule could boost the effectiveness of immunotherapies that are currently only successful in ~20% of lung cancer patients.
The Medical Minute: Understanding pulmonary nodules
Most pulmonary nodules prove harmless. But in some cases, they can be a sign of lung cancer. Learn how doctors find, test and – if necessary – remove nodules from the lungs.
Lung cancer trial of RET inhibitor selpercatinib achieves durable responses in majority of patients with RET gene fusions
For patients with non-small cell lung cancers marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses, or tumor shrinkage, in the majority of patients in a Phase I/II trial.
Structure of a Complex Enzyme That Protects Cells From DNA Damage Is Uncovered by Mount Sinai Researchers
A research team from Mount Sinai has unraveled for the first time the three-dimensional structure and mechanism of a complex enzyme that protects cells from constant DNA damage, opening the door to discovery of new therapeutics for the treatment of chemotherapy-resistant cancers.
Patient advocate can comment on the intersection of lung cancer and COVID-19
The GO2 Foundation together with other patient advocacy groups, has conducted a survey on the effect of COVID on lung cancer patients and recently participated in an expert panel event with Newswise. Biography :Chief Patient Officer at GO2 Foundation for…
“Take appropriate precautions,” key to protecting lung cancer patients during COVID pandemic, says foundation science director
The GO2 Foundation together with other patient advocacy groups, has conducted a survey on the effect of COVID on lung cancer patients and recently participated in an expert panel event with Newswise. “Now we see the pandemic kind of marching…
Newer ALK+ targeted therapy prolongs life for lung cancer patients
Patients with ALK-positive non-small cell lung cancer treated with ensartinib fared better and lived longer than those who received crizotinib, according to results of a phase 3 study. The randomized study compared the targeted therapies as first-line treatments. Ensartinib is a newer targeted therapy that was initially tested and validated at a Vanderbilt-Ingram Cancer Center research laboratory, while crizotinib received approval in 2011 from the U.S. Food and Drug Administration (FDA).
Heavier smoking linked to skyrocketing health risks
Each cigarette smoked a day by heavier smokers increases the risk of contracting some diseases by more than 30 per cent, according to a new international study published today.
Study: Enzyme Could Prove Effective in Treating Tumors and Inflammatory Diseases in Lung
Findings from a research study, led by scientists at Henry Ford, suggest an enzyme could play an important role in the treatment of cancer and autoimmune diseases in the airway.
Cancer Research Institute and The Mark Foundation for Cancer Research Launch Collaboration to Evaluate Liquid Biopsy for More Accurate and Rapid Assessment of Lung Cancer Patient Response to Immunotherapy
The Cancer Research Institute (CRI) and The Mark Foundation for Cancer Research have launched a clinical trial that aims to demonstrate the utility of a novel, ultra-sensitive biomarker-directed blood test, or liquid biopsy, in assessing cancer patient responses to immunotherapy.
U.S. News & World Report Ranks Seattle Cancer Care Alliance Among the Top Ten Cancer Hospitals in the Nation for Over 10 years
UWMC/ Seattle Cancer Care Alliance (SCCA), part of Washington state’s only National Cancer Institute (NCI)-designated comprehensive cancer center, has been recognized as the 9th Best Cancer Hospital for 2020-21 by U.S. News & World Report, and the only ranked number one cancer hospital in the Pacific Northwest for more than ten years. The annual Best Hospitals rankings and ratings, now in their 31st year, are designed to assist patients and their doctors in making informed decisions about where to receive care for challenging health conditions or for common elective procedures.
Baylor Scott & White Health Again Recognized as Most Awarded Not-for-profit Health System in Texas by U.S. News & World Report
In the midst of the extraordinary health challenge presented by the COVID-19 pandemic, Baylor Scott & White Health remains committed to quality, safe care and helping Texas communities navigate the uncertainty of the SARS-CoV-2 virus. Today, this commitment to safety and quality is recognized as U.S. News & World Report releases its 2020-2021 Best Hospitals list.
Lung Screening Bus Brings High-Tech Health Care Directly to Patients
A mobile platform for lung cancer screening with low-dose computed tomography (CT) can be developed with limited financial risk and take powerful screening tests directly to patients, including underserved rural areas where rates of new lung cancer cases tend to be higher.
Hackensack University Medical Center Becomes First in New Jersey to Perform Revolutionary Minimally Invasive Robotic Lung Biopsy Procedure
More than 70% of lung nodules that need to be biopsied (analyzed to see if they are cancer) reside far out in the periphery of the lung, making them very difficult to biopsy using conventional bronchoscopy (a tube with a camera on its tip inserted through a patient’s mouth into the lungs). The Ion system combines computed tomography (CT) data and robotic-assisted surgical technology to facilitate and expedite access to these nodules. The entire procedure is performed through bronchoscopy, without the need for any external surgical incisions.
Yale Cancer Center Awarded NIH SPORE Renewal for Lung Cancer Research
Yale Cancer Center researchers were awarded a $11 million grant renewal from the National institutes of Health to fund the Yale Specialized Program of Research Excellence (SPORE) in Lung Cancer.
Expanded Efforts, Focused Approach
Physicians and scientists at The University of Kansas Cancer Center are committed to improving lung cancer outcomes in Kansas.
Neural network can determine lung cancer severity
NIBIB-funded researchers at Stanford University have created an artificial neural network that analyzes lung CT scans to provide information about lung cancer severity that can guide treatment options.
Monoclonal Antibody Restores T-Cell Ability to Kill Cancer
A new class of anticancer agents can restore the ability of cytotoxic T lymphocytes (CTLs) to infiltrate the tumor and kill target cells in patients with metastatic non-small cell lung cancer (mNSCLC).
Memorial Sloan Kettering Awards & Appointments
Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.